Table 1 Clinical data and prognosis of the included submacular hemorrhage patients
Case/age (years)/sex/side/disease | Treatment before SMH | GLD /height (μm) | Foveal involvement | Special feature | Interval (days) | Surgery details | Preoperative BCVA (logMAR) | Final BCVA (logMAR) | Follow-up (days) | SMH prognosis | Visual prognosis | Complications |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
1/80/M/OD/RAM | IVR × 1 | 5609/1200 | Yes | Large SMH, preretinal hemorrhage and retinal break | 14 | PPV + ICG + ILM peeling + rt-PA + air-fluid exchange + endolaser + silicone | 2.30 | 1.30 | 100 | Complete absorption | Improved | No |
2/17/M/OS/traumatic retinopathy | Retrobulbar GC × 2 | 3559/491 | Yes | Large SMH | 11 | PPV + ICG + ILM peeling + rt-PA + 14% C3F8 | 1.00 | 0.10 | 157 | Complete absorption | Improved | No |
3/80/M/OS/PCV | IVA × 1 | NA/NA | Yes | VH, large SMH, hemorrhagic PED and severe cataract | 180 | Phaco + PPV + ICG + ILM peeling + rt-PA + IOL + 14% C3F8 | 2.60 | 2.60 | 123 | Recurrent VH, SMH and hyphema | Stable | Recurrent VH, SMH, hyphema and secondary PPV with silicone tamponade |
4/20/M/OD/traumatic retinopathy | No treatment | 2985/529 | Yes | Large SMH | 12 | PPV + ICG + ILM peeling + rt-PA + 14% C3F8 | 1.85 | 1.00 | 96 | Partial absorption | Improved | No |
5/68/M/OS/RAM | FPC × 1 | NA/NA | Yes | Large SMH | 7 | Phaco + PPV + ICG + ILM peeling + rt-PA + IOL + 14% C3F8 | 1.00 | 0.40 | 184 | Complete absorption | Improved | No |
6/68/F/OD/PCV | No treatment | 8742/715 | Yes | Large SMH | 7 | PPV + ICG + ILM peeling + rt-PA + 14% C3F8 + IVA × 1 | 1.00 | 0.52 | 90 | Complete absorption | Improved | No |
7/66/F/OD/nAMD | PDT × 1 + IVC × 7 | 6821/553 | Yes | Large SMH | 30 | PPV + ICG + ILM peeling + rt-PA + 14% C3F8 + IVA × 1 | 0.92 | 0.40 | 99 | Complete absorption | Improved | No |
8/65/M/OD/RAM | No treatment | 7786/1069 | Yes | Large SMH | 20 | Phaco + PPV + ICG + ILM peeling + rt-PA + IOL + 14% C3F8 | 1.52 | 1.00 | 131 | Complete absorption | Improved | Delayed RD and secondary PPV |
9/73/M/OD/PCV | IVA × 6 | 8755/728 | Yes | VH, large SMH and hemorrhagic RD | 15 | Phaco + PPV + ICG + ILM peeling + rt-PA + IOL + 14% C3F8 | 2.30 | 0.92 | 143 | Complete absorption | Improved | No |
10/69/M/OD/PCV | IVA × 3 | 7364/1884 | Yes | VH and large SMH | 90 | Phaco + PPV + ICG + ILM peeling + rt-PA + IOL + 14% C3F8 + IVA × 1 | 1.70 | 1.70 | 95 | No absorption | Stable | No |
11/72/M/OD/PCV | No treatment | 11,860/1340 | Yes | Large SMH | 10 | Phaco + PPV + ICG + ILM peeling + rt-PA + IOL + 14% C3F8 | 1.00 | 0.82 | 198 | Complete absorption | Improved | No |
12/70/F/OD/PCV | IVC × 1 | NA/NA | Yes | VH, large SMH and hemorrhagic PED | 14 | PPV + ICG + ILM peeling + rt-PA + 14% C3F8 | 2.30 | 2.30 | 131 | Recurrent VH, SMH and hyphema | Stable | Recurrent VH, SMH, hyphema and secondary PPV with silicone tamponade |
13/69/M/OD/PCV | IVA × 12 | 5319/NA | Yes | Large SMH | 90 | PPV + ICG + ILM peeling + rt-PA + endolaser + 14% C3F8 + IVA × 1 | 2.30 | 2.60 | 148 | Partial absorption | Worsened | RD and secondary PPV with silicone tamponade |
14/67/M/OD/PCV | IVA × 3 | NA/NA | Yes | VH and large SMH | 60 | Phaco + PPV + ICG + ILM peeling + rt-PA + IOL + 14% C3F8 | 2.60 | 2.30 | 116 | Partial absorption | Improved | No |
15/45/F/OD/PCV | IVC × 3 | NA/NA | Yes | VH and large SMH | 30 | PPV + ICG + ILM peeling + rt-PA + 14% C3F8 | 2.30 | 0.60 | 125 | Partial absorption | Improved | No |
16/71/F/OS/RAM | No treatment | 4340/825 | Yes | Large SMH | 60 | Phaco + PPV + ICG + ILM peeling + rt-PA + IOL + 14% C3F8 | 2.00 | 0.82 | 99 | Partial absorption | Improved | No |
17/60/F/OD/PCV | No treatment | NA/NA | Yes | VH and large SMH | 15 | PPV + ICG + ILM peeling + rt-PA + 14% C3F8 | 2.30 | 1.00 | 99 | Partial absorption | Improved | No |
18/57/F/OS/RAM | No treatment | 5318/977 | Yes | VH and large SMH | 24 | PPV + rt-PA + TA + ICG + air-fluid exchange + 10% C3F8 | 2.30 | 0.22 | 225 | Complete absorption | Improved | No |